REG-Alvotech Q1 2026 Financial Results
Alvotech reported Q1 2026 revenue of $105.9 million, down from $132.8 million in the prior year, citing a production slowdown tied to quality system improvements and FDA resubmission preparations. Despite the quarterly dip, the company raised full-year 2026 guidance, projecting revenue of $650–$700 million and adjusted EBITDA of $180–$220 million.
Key figures
- Revenue
- 105900000
- Guidance
- 2026 total revenue $650-$700M; adjusted EBITDA $180-$220M
- Revenue Yoy
- $105.9m vs $132.8m (decline)
- Gross margin
- 57%
- Adjusted ebitda
- 24400000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.